Skip to main content
Top
Published in: Heart and Vessels 1/2014

01-01-2014 | Original Article

Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol

Authors: Manabu Ogita, Katsumi Miyauchi, Tadashi Miyazaki, Ryo Naito, Hirokazu Konishi, Shuta Tsuboi, Tomotaka Dohi, Takatoshi Kasai, Takayuki Yokoyama, Shinya Okazaki, Takeshi Kurata, Hiroyuki Daida

Published in: Heart and Vessels | Issue 1/2014

Login to get access

Abstract

Diabetes mellitus is recognized an independent risk factor for coronary artery disease (CAD) and mortality. Clinical trials have shown that statins significantly reduce cardiovascular events in diabetic patients. However, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein cholesterol (LDL-C) levels with statin. High-density lipoprotein cholesterol (HDL-C) is an established coronary risk factor that is independent of LDL-C levels. We evaluated the impact of HDL-C on long-term mortality in diabetic patients with stable CAD who achieved optimal LDL-C. We enrolled 438 consecutive diabetic patients who were scheduled for percutaneous coronary intervention between 2004 and 2007 at our institution. We identified 165 patients who achieved target LDL-C <100 mg/dl. Patients were stratified into two groups according to HDL-C levels (low HDL-C group, baseline HDL-C <40 mg/dl; high HDL-C group, ≥40 mg/dl). Major adverse cardiac events (MACE) that included all-cause death, acute coronary syndrome, and target lesion revascularization were evaluated between the two groups. The median follow-up period was 946 days. The rate of MACE was significantly higher in diabetic patients with low-HDL-C who achieved optimal LDL-C (6.9 vs 17.9 %, log-rank P = 0.030). Multivariate Cox regression analysis showed that HDL-C is significantly associated with clinical outcomes (adjusted hazard ratio for MACE 1.33, 95 % confidence interval 1.01–1.75, P = 0.042). Low HDL-C is a residual risk factor that is significantly associated with long-term clinical outcomes among diabetic patients with stable CAD who achieve optimal LDL-C levels.
Literature
1.
go back to reference Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035–2038PubMedCrossRef Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035–2038PubMedCrossRef
3.
go back to reference Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, Levy D, Fox CS (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:728–1735 Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, Levy D, Fox CS (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:728–1735
4.
go back to reference Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J (1998) Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 21:69–75PubMedCrossRef Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J (1998) Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 21:69–75PubMedCrossRef
5.
go back to reference Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef
6.
go back to reference Nasu K, Tsuchikane E, Kato O, Fujita H, Surmely JF, Ehara M, Kinoshita Y, Tanaka N, Matsubara T, Asakura Y, Terashima M, Suzuki T (2008) Plaque characterization by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 94:429–433PubMedCrossRef Nasu K, Tsuchikane E, Kato O, Fujita H, Surmely JF, Ehara M, Kinoshita Y, Tanaka N, Matsubara T, Asakura Y, Terashima M, Suzuki T (2008) Plaque characterization by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 94:429–433PubMedCrossRef
7.
go back to reference Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K, Yamazaki M, Hasegawa G, Oda Y, Nakamura N (2012) Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels 27:160–165PubMedCrossRef Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K, Yamazaki M, Hasegawa G, Oda Y, Nakamura N (2012) Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels 27:160–165PubMedCrossRef
8.
go back to reference Farrag A, Bakhoum S, Salem MA, El-Faramawy A, Gergis E (2011) The association between extracoronary calcification and coronary artery disease in patients with type 2 diabetes mellitus. Heart Vessels. doi: 10.1007/s00380-011-0205-6 Farrag A, Bakhoum S, Salem MA, El-Faramawy A, Gergis E (2011) The association between extracoronary calcification and coronary artery disease in patients with type 2 diabetes mellitus. Heart Vessels. doi: 10.​1007/​s00380-011-0205-6
9.
10.
go back to reference Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H (2008) Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels 23:149–154PubMedCrossRef Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H (2008) Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels 23:149–154PubMedCrossRef
11.
go back to reference Colhoun HM, Bettteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, on behalf of the CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDs): multicenter randomized placebo-controlled trial. Lancet 364:685–696 Colhoun HM, Bettteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, on behalf of the CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDs): multicenter randomized placebo-controlled trial. Lancet 364:685–696
12.
go back to reference Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRef Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRef
13.
go back to reference Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835–2838PubMedCrossRef Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835–2838PubMedCrossRef
14.
go back to reference Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis Risk in Communities Study Group (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108–1113 Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis Risk in Communities Study Group (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108–1113
15.
go back to reference The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 53:450–467 The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 53:450–467
16.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
17.
go back to reference Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M (2007) Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14:45–50PubMedCrossRef Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M (2007) Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14:45–50PubMedCrossRef
18.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRef
19.
go back to reference The Examination Committee of Criteria for Metabolic Syndrome (2005) Definition and criteria of metabolic syndrome. J Jpn Soc Int Med 94:794–809 (in Japanese)CrossRef The Examination Committee of Criteria for Metabolic Syndrome (2005) Definition and criteria of metabolic syndrome. J Jpn Soc Int Med 94:794–809 (in Japanese)CrossRef
21.
go back to reference Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129–2140PubMedCrossRef Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129–2140PubMedCrossRef
22.
go back to reference Jacobs MJ, Kleisli T, Pio JR, Malik S, L’ltalien GJ, Chen RS, Wong ND (2005) Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 70:263–269PubMedCrossRef Jacobs MJ, Kleisli T, Pio JR, Malik S, L’ltalien GJ, Chen RS, Wong ND (2005) Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 70:263–269PubMedCrossRef
23.
go back to reference Bruckert E, Baccara-Dinet M, Eschwege E (2007) Low HDL-cholesterol is common in European type 2 diabetic patients receiving treatment for dyslipidemia: data from a pan-European survey. Diabet Med 24:388–391PubMedCrossRef Bruckert E, Baccara-Dinet M, Eschwege E (2007) Low HDL-cholesterol is common in European type 2 diabetic patients receiving treatment for dyslipidemia: data from a pan-European survey. Diabet Med 24:388–391PubMedCrossRef
24.
go back to reference Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310PubMedCrossRef Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310PubMedCrossRef
25.
go back to reference Goldbourt U, Yaari S, Medalie JH (1997) Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 17:107–113PubMedCrossRef Goldbourt U, Yaari S, Medalie JH (1997) Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 17:107–113PubMedCrossRef
26.
go back to reference Miller M, Kwiterovich PO Jr (1990) Isolated low HDL cholesterol as an important risk factor for coronary heart disease. Eur Heart J Suppl H:9–14 Miller M, Kwiterovich PO Jr (1990) Isolated low HDL cholesterol as an important risk factor for coronary heart disease. Eur Heart J Suppl H:9–14
27.
go back to reference Ueshima H, Iida M, Shimamoto T, Konishi M, Tanigaki M, Nakanishi N, Takayama Y, Ozawa H, Kojima S, Komachi Y (1982) High-density lipoprotein-cholesterol levels in Japan. JAMA 247:1985–1987PubMedCrossRef Ueshima H, Iida M, Shimamoto T, Konishi M, Tanigaki M, Nakanishi N, Takayama Y, Ozawa H, Kojima S, Komachi Y (1982) High-density lipoprotein-cholesterol levels in Japan. JAMA 247:1985–1987PubMedCrossRef
28.
go back to reference Ko M, Kim MT, Nam JJ (2006) Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 110:184–190PubMedCrossRef Ko M, Kim MT, Nam JJ (2006) Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 110:184–190PubMedCrossRef
29.
go back to reference Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, Chew SK, Chia KS, Tan CE, Tai ES (2006) Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 186:367–373PubMedCrossRef Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, Chew SK, Chia KS, Tan CE, Tai ES (2006) Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 186:367–373PubMedCrossRef
30.
go back to reference Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H, The NIPPON DATA90 Research Group (2006) The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 184:143–150PubMedCrossRef Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H, The NIPPON DATA90 Research Group (2006) The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 184:143–150PubMedCrossRef
31.
go back to reference Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, Shaw J, Ueshima H, Zimmet P, Jee SH, Patel JV, Caterson I, Perkovic V, Woodward M, for the Asia Pacific Cohort Studies Collaboration and the Obesity in Asia Collaboration (2011) Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 124:2056–2064PubMedCrossRef Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, Shaw J, Ueshima H, Zimmet P, Jee SH, Patel JV, Caterson I, Perkovic V, Woodward M, for the Asia Pacific Cohort Studies Collaboration and the Obesity in Asia Collaboration (2011) Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 124:2056–2064PubMedCrossRef
32.
go back to reference Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM, Park CS, Kim PJ, Moon KW, Chang K, Kim HY, Yoo KD, Jeon DS, Chung WS, Park YG, Seung KB, Catholic University of Korea, Percutaneous Coronary Intervention Registry Investigators (2011) High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 97:1942–1950CrossRef Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM, Park CS, Kim PJ, Moon KW, Chang K, Kim HY, Yoo KD, Jeon DS, Chung WS, Park YG, Seung KB, Catholic University of Korea, Percutaneous Coronary Intervention Registry Investigators (2011) High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 97:1942–1950CrossRef
33.
34.
go back to reference Natarajan P, Ray KK, Cannon CP (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55:1283–1299PubMedCrossRef Natarajan P, Ray KK, Cannon CP (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55:1283–1299PubMedCrossRef
35.
go back to reference Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M (2010) Molecular mechanisms of HDL-cholesterol elevation by statins and its effects of on HDL functions. J Atheroscler Thromb 17:436–451PubMedCrossRef Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M (2010) Molecular mechanisms of HDL-cholesterol elevation by statins and its effects of on HDL functions. J Atheroscler Thromb 17:436–451PubMedCrossRef
36.
go back to reference Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators (2007) Effects of toracetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122PubMedCrossRef Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators (2007) Effects of toracetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122PubMedCrossRef
37.
go back to reference Schwartz GG, Olsson AG, Abt M, Ballantyne CM, barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tradif JC, Wright RS, dal OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099 Schwartz GG, Olsson AG, Abt M, Ballantyne CM, barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tradif JC, Wright RS, dal OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099
38.
go back to reference Investigators AIM-HIGH (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267CrossRef Investigators AIM-HIGH (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267CrossRef
39.
go back to reference Nichols GA, Vupputuri S, Rosales AG (2011) Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol 108:1124–1128PubMedCrossRef Nichols GA, Vupputuri S, Rosales AG (2011) Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol 108:1124–1128PubMedCrossRef
40.
go back to reference Brown BG, Zhao XQ (2008) Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 101:58B–62BPubMedCrossRef Brown BG, Zhao XQ (2008) Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 101:58B–62BPubMedCrossRef
41.
go back to reference Hewing B, Fisher EA (2012) Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol 23:372–376PubMedCrossRef Hewing B, Fisher EA (2012) Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol 23:372–376PubMedCrossRef
42.
go back to reference Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, FIELD study investigators (2009) The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 32:493–498PubMedCrossRef Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, FIELD study investigators (2009) The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 32:493–498PubMedCrossRef
43.
go back to reference Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002) Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162:2597–2604PubMedCrossRef Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002) Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162:2597–2604PubMedCrossRef
Metadata
Title
Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol
Authors
Manabu Ogita
Katsumi Miyauchi
Tadashi Miyazaki
Ryo Naito
Hirokazu Konishi
Shuta Tsuboi
Tomotaka Dohi
Takatoshi Kasai
Takayuki Yokoyama
Shinya Okazaki
Takeshi Kurata
Hiroyuki Daida
Publication date
01-01-2014
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 1/2014
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-013-0330-5

Other articles of this Issue 1/2014

Heart and Vessels 1/2014 Go to the issue